0001104659-24-030156.txt : 20240301
0001104659-24-030156.hdr.sgml : 20240301
20240301204527
ACCESSION NUMBER: 0001104659-24-030156
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ali Asif
CENTRAL INDEX KEY: 0001921163
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37852
FILM NUMBER: 24712590
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc
CENTRAL INDEX KEY: 0001377121
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 980505495
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
BUSINESS PHONE: (510) 474-0170
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Therapeutics Inc
DATE OF NAME CHANGE: 20130605
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Inc
DATE OF NAME CHANGE: 20061002
4
1
tm247765-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-02-29
0
0001377121
Protagonist Therapeutics, Inc
PTGX
0001921163
Ali Asif
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
NEWARK
CA
94560-1160
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-02-29
4
S
0
7850
30.61
D
42734
D
Common Stock
2024-02-29
4
S
0
2089
31.00
D
40645
D
Common Stock
2024-03-01
4
M
0
12000
12.17
A
52645
D
Common Stock
2024-03-01
4
S
0
12000
32.22
D
40645
D
Common Stock
2024-03-01
4
S
0
2248
32.33
D
38397
D
Stock Option (right to buy)
12.17
2024-03-01
4
M
0
12000
0.00
D
2033-01-15
Common Stock
12000
51750
D
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant.
/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali
2024-03-01